Patent · US Active

Uses of antibodies to interleukin-6 in cancer treatment

US9758580B2 · kind B2 · utility

1Cited by

0References

15Claims

0Family size

Assignee

Fountain Biopharma Inc. · TW

Inventors

Tong-Young Lee · Taipei, TW
Han-Chung Wu · Taipei, TW
Tanny Chen Tsao · Taipei, TW
Willie Lin · Taipei, TW

Key dates

Filing date	Dec 31, 2015
Grant date	Sep 12, 2017
Priority date	—
Expiry date	Dec 31, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.